Photo

Osteoporosis Overview

  • Definition: Osteoporosis is characterized by decreased bone strength leading to an increased risk of fractures.

    • Primarily affects postmenopausal women, but men and younger adults can also be impacted due to aging and underlying conditions.

  • Clinical Manifestations:

    • Common manifestations include vertebral and hip fractures, but fractures can occur throughout the skeleton.

    • Affects more than 10 million individuals in the U.S., but a significant number remain undiagnosed.

  • Statistics:

    • Lifetime risk of hip fractures: ~50% for postmenopausal Caucasian women; ~25% for men at 50.

    • Approximately 300,000 hip fractures occur annually in the U.S., primarily requiring hospitalization and surgery.

    • Fractures related to osteoporosis lead to high morbidity and mortality rates, particularly in the elderly.

Epidemiology of Osteoporosis

  • 10.8 million women and 2.5 million men have osteoporosis as defined by bone mineral density.

  • ~2 million osteoporosis-related fractures occur each year in the U.S. at a cost of $19 billion, expected to rise to $25 billion by 2025.

  • Increased fracture risks and subsequent complications widely impact survivors, with up to 30% requiring long-term care.

Risk Factors

  • Non-modifiable:

    • Age, female gender, advanced age, genetics (family history of fractures), and race (Caucasian).

  • Modifiable:

    • Lifestyle factors like poor nutrition, lack of physical activity, smoking, excessive alcohol consumption, chronic diseases with inflammatory components, and certain medications such as glucocorticoids.

Pathophysiology

  • Osteoporosis results from an imbalance between bone resorption and bone formation, primarily affecting trabecular (spongy) bone without clear symptoms.

  • Bone Remodeling Process:

    • Involves osteoblasts (bone-building cells) and osteoclasts (bone-resorbing cells).

    • Factors influencing remodeling include hormones (estrogen, PTH, vitamin D) and physical activity levels.

Diagnostic Criteria

  • Diagnosis commonly uses Dual-energy X-ray Absorptiometry (DXA) scanning.

    • Osteoporosis diagnosed when T-score is less than -2.5 standard deviations below the young adult mean.

    • Low bone mass (T-score between -1 and -2.5) indicates increased risk of fractures.

Treatment Strategies

  • Lifestyle Modifications:

    • Adequate intake of calcium and vitamin D, regular exercise focusing on weight-bearing activities, and fall prevention strategies.

  • Pharmacologic Treatments:

    1. Antiresorptive Agents:

      • Bisphosphonates (e.g., Alendronate, Risedronate, Zoledronic acid) reduce fracture risk.

      • SERMs (Selective Estrogen Receptor Modulators) such as Raloxifene provide fracture reduction benefits.

    2. Anabolic Agents:

      • Parathyroid hormone analogs like Teriparatide stimulate new bone formation.

      • Abaloparatide, another PTH analog, has also shown positive results in BMD and fracture incidence.

    3. Denosumab:

      • A monoclonal antibody against RANKL that inhibits osteoclast formation and function, effectively increasing BMD and reducing fracture risk.

Monitoring Treatment Response

  • Regular monitoring of BMD via DXA scans to assess ongoing treatment effectiveness.

  • Treatment adjustments may be required based on significant changes in bone density or increased fracture risk.

Conclusion

  • Osteoporosis is a major public health concern with significant implications for patient morbidity and healthcare costs.

  • Early identification, lifestyle modification, and effective pharmacologic therapy can drastically reduce risks associated with this condition.